Compare BridgeBio Pharma Inc (BBIO) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs SiTime Corporation — how do they compare? BridgeBio Pharma Inc trades at $82.37 (market cap $16.46B), while SiTime Corporation trades at $587.08 (market cap $18.72B). The key difference: BridgeBio Pharma Inc and SiTime Corporation are close in size by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| BBIO | SITM | |
|---|---|---|
Market Cap | $16.46B | $18.72B |
Sector | Health | Technology |
52-Week High | $90.17 | $901.60 |
52-Week Low | $44.81 | $190.16 |
Enterprise Value | $18.02B | $17.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
SITM trades at $602.55, down 4.2% over 24 hours, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth and expanding gross margins, driven by AI infrastructure demand and the completed Renesas acquisition. Analyst consensus remains unanimously bullish with a $743.75 price target, though negative net income and high valuation ratios present fundamental concerns.
Outlook is mixed: robust AI-driven growth and strategic acquisitions offer upside, but profitability challenges and bearish technicals near-term pose risks. Investors should weigh strong analyst support against cash flow volatility and execution risks in integrating new assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
